Literature DB >> 8365093

The five-year incidence of blindness after introducing a screening programme for early detection of treatable diabetic retinopathy.

E Agardh1, C D Agardh, C Hansson-Lundblad.   

Abstract

The incidence of moderate visual impairment and blindness due to diabetic retinopathy was studied 5 years after introducing a screening system for early detection of treatable retinopathy. Photocoagulation was performed in patients with clinically significant macular oedema, severe preproliferative, and proliferative retinopathy. Eighty-eight percent of 470 Type 1 and 88% of 388 Type 2 diabetic patients were still available for follow-up. In the Type 1 group, the five-year incidence of blindness and moderate visual impairment were 0.5% and 1.2%, respectively. Corresponding figures for the Type 2 diabetic patients were 0.6% and 1.7%, respectively. The majority of patients with loss of vision had severe retinopathy at baseline. Among those who entered the screening programme with no or mild retinopathy, loss of vision occurred in only one of the Type 1 and four of the Type 2 diabetic patients. It is concluded that the risk for visual impairment and blindness due to diabetes can be substantially reduced by using programmes for early detection of and effective treatment of diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8365093     DOI: 10.1111/j.1464-5491.1993.tb00120.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  15 in total

1.  Prevention of diabetic blindness.

Authors:  E Stefánsson
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

Review 2.  Clinical and Psychosocial Factors Influencing Retinal Screening Uptake Among Young Adults with Type 2 Diabetes.

Authors:  A J Lake; G Rees; J Speight
Journal:  Curr Diab Rep       Date:  2018-05-24       Impact factor: 4.810

3.  The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy.

Authors:  Ronald Klein; Kristine E Lee; Ronald E Gangnon; Barbara E K Klein
Journal:  Ophthalmology       Date:  2009-10-31       Impact factor: 12.079

4.  Incidence of blindness due to diabetic eye disease in Fife 1990-9.

Authors:  T G Cormack; B Grant; M J Macdonald; J Steel; I W Campbell
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

5.  Clinical characteristics influence screening intervals for diabetic retinopathy.

Authors:  Massimo Porta; Mauro Maurino; Sara Severini; Elena Lamarmora; Marina Trento; Elena Sitia; Eleonora Coppo; Alessandro Raviolo; Stefania Carbonari; Marcello Montanaro; Lorenza Palanza; Paola Dalmasso; Franco Cavallo
Journal:  Diabetologia       Date:  2013-07-05       Impact factor: 10.122

6.  Use of eye care services by people with diabetes: the Melbourne Visual Impairment Project.

Authors:  C A McCarty; C W Lloyd-Smith; S E Lee; P M Livingston; Y L Stanislavsky; H R Taylor
Journal:  Br J Ophthalmol       Date:  1998-04       Impact factor: 4.638

7.  Screening for diabetic retinopathy.

Authors:  D M Squirrell; J F Talbot
Journal:  J R Soc Med       Date:  2003-06       Impact factor: 18.000

8.  Prevalence and progression of visual impairment in patients newly diagnosed with clinical type 2 diabetes: a 6-year follow up study.

Authors:  Niels de Fine Olivarius; Volkert Siersma; Gitte Juul Almind; Niels Vesti Nielsen
Journal:  BMC Public Health       Date:  2011-02-04       Impact factor: 3.295

9.  Ethnic variation in the prevalence of visual impairment in people attending diabetic retinopathy screening in the United Kingdom (DRIVE UK).

Authors:  Sobha Sivaprasad; Bhaskar Gupta; Martin C Gulliford; Hiten Dodhia; Samantha Mann; Dinesh Nagi; Jennifer Evans
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

Review 10.  Extending the diabetic retinopathy screening interval beyond 1 year: systematic review.

Authors:  Sian Taylor-Phillips; Hema Mistry; Rachael Leslie; Dan Todkill; Alexander Tsertsvadze; Martin Connock; Aileen Clarke
Journal:  Br J Ophthalmol       Date:  2015-01-13       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.